30th Jun 2016 11:23
LONDON (Alliance News) - Irish pharmaceuticals company Shire PLC on Thursday said its SHP607 treatment for retinopathy in extremely premature infants did not meet its primary endpoint.
Shire said the treatment failed to meet the goals of reducing the severity of retinopathy, a rare eye condition, though it did demonstrate statistically significant effects in secondary endpoints.
"Although the study did not meet its primary endpoint, we are extremely encouraged by the topline secondary endpoints related to lung and brain. For severe complications related to the lung and brain, there are no approved treatment options, and these data support our commitment to further investigate the potential systemic benefits of SHP607 in this population where the unmet patient need is substantial," said Philip Vickers, head of research and development at Shire.
Shire shares were up 1.2% to 4,526.00 pence Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire